Opendata, web and dolomites

SPOT SIGNED

SPOT - Synthesis of Pretargeted Oncology Theranostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPOT project word cloud

Explore the words cloud of the SPOT project. It provides you a very rough idea of what is the project "SPOT" about.

surface    intact    injected    tco    dbco    docetaxel    fragments    diagnosis    azide    tissue    noise    gemcitabine    penetration    chances    animal    acid    sulfide    deep    vivo    pretargeted    prognosis    drawbacks    attached    adenocarcinoma    tumor    click    fall    multivalent    lactic    site    poor    chemotherapeutic    moieties    carriers    treatment    cycloaddition    alginate    size    tested    dibenzocyclooctyne    nps    cyclooctene    antibodies    exclusive    shielding    bioorthogonal    pdca    healthy    subsequently    spot    trans    pancreatic    conjugated    small    xenografts    np    extremely    delivering    functionalized    contrast    benefits    drug    preforming    positive    generation    reaction    overcome    accumulation    ligands    action    capacities    poly    zone    ductal    pdac    clickable    groups    probes    model    tetrazine    whereby    nanoparticle    outcome    lost    cancer    silver    gaining    clearance    ratio    encapsulated    hyaluronic    immunological    active    imaging    ab    additionally    opponent    electrospraying    undergo    ideal    visualization   

Project "SPOT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD COMPLUTENSE DE MADRID 

Organization address
address: AVENIDA DE SENECA 2
city: MADRID
postcode: 28040
website: http://www.ucm.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 160˙932 €
 EC max contribution 160˙932 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD COMPLUTENSE DE MADRID ES (MADRID) coordinator 160˙932.00

Map

 Project objective

To overcome size-related drawbacks of intact antibodies (Ab) for active tumor targeting, small but multivalent Ab-fragments, which fall in the “ideal tumor targeting zone”, are gaining increasing interest. However, the achieved benefits of Ab-fragments are lost when conjugated to imaging probes or drug carriers. Therefore, the SPOT action is going to focus on the generation of small Ab-fragments with highly specific targeting capacities and deep tissue penetration that are able to subsequently undergo a bioorthogonal click reaction at the tumor site. As cancer model, pancreatic ductal adenocarcinoma (PDAC), which currently still has an extremely poor prognosis, is going to be targeted. Two different click reaction will be evaluated: The cycloaddition between tetrazine and trans-cyclooctene (TCO) as well as azide and dibenzocyclooctyne (DBCO), whereby the Ab-fragments are functionalized with the TCO and DBCO groups. The opponent moieties are attached to alginate and hyaluronic acid-based ligands, which are subsequently introduced to the nanoparticle’s (NP) surface, additionally providing shielding from the immunological system. After the accumulation of the clickable Ab-fragments at the tumor site and their clearance from healthy tissue, the imaging or drug-delivering NPs with the opponent clickable moieties are injected, allowing for their exclusive accumulation at the pretargeted tumor site. For effective visualization of PDAC tissue, state-of-the-art silver sulfide NPs, with a high contrast-to-noise ratio and deep tissue imaging, are applied. The use of these NPs can be a significant step towards early PDCA diagnosis and therefore providing better chances for a positive treatment outcome. For the pretargeted drug-delivery approach, poly(lactic acid)-based NPs with encapsulated gemcitabine or docetaxel generated via electrospraying are going to be tested as a potential chemotherapeutic approach for PDAC, preforming small animal in vivo studies with PDAC xenografts.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPOT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPOT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

CLIMACY (2020)

Practices of Climate Diplomacy and Uneven Policy Responses on Climate Change on Human Mobility

Read More  

STMICRO (2020)

Space-time visualization of microelectronic chip operation with femtosecond electron microscopy

Read More